Getting Back On The EU Agenda Is Uppermost For Swiss Medtech Industry
Executive Summary
The Swiss medtech market is now served by 1,200 companies fewer than when its MRA with the EU was still in force. A renewal of the agreement is not a lost hope for the local industry, but at present it is a distant prospect.
You may also be interested in...
Swiss Initiative To Monitor Missing Medical Devices To Manage Current Product Crisis
The ongoing availability of many medical devices in Switzerland is threatened even more severely than in the EU. Medtech Insight spoke to two key life science experts to understand why this is and to hear the solutions they are proposing.
Swiss Parliament’s Vote For Medtech Innovation Succeeds
Another key stage has been reached in Switzerland’s bid to enable US FDA-approved medtech to be used in the local population.
Switzerland Moves Closer To Accepting US FDA-Approved Medtech
EU market continuity and renewing the MRA remain top priorities for the Swiss medtech industry and market. But alongside that runs an ambitious plan to allow US-approved devices into Switzerland.